Dr Tingbo Liang and colleagues determined the outcomes of liver transplant recipients receiving lamivudine in combination or monotherapy.
The research team assessed lamivudine combined with low-dose intramuscular Hepatitis B Immunoglobulin therapy.
The team retrospectively reviewed the medical records of patients that had had liver transplantation in a single center for Hepatitis B-related liver diseases.
The researchers noted that a total of 165 patients had received liver transplantation from 1999 to 2004.
The team found that 51 patients received lamivudine monotherapy, and 114 received combined prophylaxis post-liver transplantation.
The mean follow-up was 20 months.
| The 1-year recurrence rate with combined prophylaxis was 14%|
The researchers observed that Hepatitis B relapsed in 21 patients of the hepatitis B surface antigen carriers who received the monotherapy.
The 1-year and 2-year actuarial risk was 27% and 40%, respectively.
Recurrence occurred in 16 patients of 114 patients receiving the combined prophylaxis, with a 1- and 2-year recurrence rate of 14% and 15%.
A total of 25 cases with YMDD mutants were detected in all the 37 patients.
The team found the mutation in 14 cases of the monotherapy group and in 11 cases in the combination group.
Dr Liang's team concluded, “Lamividine monotherapy and low-dose intramuscular Hepatitis B immunoglobulin treatment demonstrates a better result than lamividine monotherapy, as prophylaxis against post-liver transplant reinfection of the graft.”
“However, the safety and efficacy as a substitution for high-dose intravenous Hepatitis B immunoglobulin with lamividine monotherapy needs to be investigated further.”